| Literature DB >> 20087442 |
Ellen Van Damme1, Kris Laukens, Thanh Hai Dang, Xaveer Van Ostade.
Abstract
Promyelocytic Leukaemia Protein nuclear bodies (PML-NBs) are dynamic nuclear protein aggregates. To gain insight in PML-NB function, reductionist and high throughput techniques have been employed to identify PML-NB proteins. Here we present a manually curated network of the PML-NB interactome based on extensive literature review including database information. By compiling 'the PML-ome', we highlighted the presence of interactors in the Small Ubiquitin Like Modifier (SUMO) conjugation pathway. Additionally, we show an enrichment of SUMOylatable proteins in the PML-NBs through an in-house prediction algorithm. Therefore, based on the PML network, we hypothesize that PML-NBs may function as a nuclear SUMOylation hotspot.Entities:
Keywords: Cytoscape; PML-NB; SUMOylation; network; protein-protein interaction
Mesh:
Substances:
Year: 2010 PMID: 20087442 PMCID: PMC2808052 DOI: 10.7150/ijbs.6.51
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1Schematic representation of the SUMOylation pathway. Before conjugation, immature SUMO is processed by SUMO specific proteases (SENPs) to expose two C-terminal glycine residues required for conjugation. After processing, mature SUMO is activated in an ATP dependent manner by E1 enzymes AOS1 and UBA2. Subsequently, SUMO is transferred to E2 conjugation enzyme UBC9 and finally conjugated to a target protein by an E3 ligase. SUMO conjugation can be reversed by protease activity of SENPs thereby releasing free SUMO and target. K= Lysine residue.
The SENP isoforms show different affinity for the several SUMO isoforms in maturation processing and de-conjugation.
| SENP isoform | Maturation | De-conjugation |
|---|---|---|
| SENP1 | SUMO1>SUMO2>>SUMO3 | SUMO1, SUMO2 |
| SENP2 | SUMO2>SUMO1, poor activity towards SUMO3 | SUMO2>SUMO1, poor activity towards SUMO3 |
| SENP3 | No processing activity | SUMO2, SUMO3 |
| SENP5 | SUMO3 | SUMO1 |
| SENP6 | No processing activity | SUMO2, SUMO3 |
| SENP7 | No processing activity | SUMO2, SUMO3>>>SUMO1 |
Figure 2A manually curated PML-NB network. The central node is the scaffold protein PML. PML-NB components are connected to PML. Black edges represent protein components found in any of the databases (MINT, BIOGRID, IntAct, NPD, HRPD), pink edges were exclusively found in literature. We also represent the interactions between PML-NB components which are depicted as blue edges. For each node we provided the canonical name. Boxed components are those exclusively found in ALT cells.
Overview of the different node and edge attributes in the PML-NB interaction network. In the 'field' column we present the attribute as it is assigned in the network. In the 'description' column we provide a brief explanation of what is embodied by the attribute. Finally, in the 'criteria' column the different sources of information are mentioned.
| Field | Description | Criteria (in order) |
|---|---|---|
| ID | UniProtID | Retrieved from UniProt |
| Canonical Name | Common name | Most used in literature > First designation in UniProt |
| Cellular Localization | Subcellular localization differentiates amongst the several organelles in the nucleus and cytoplasm. | GO (cellular component ontology) > Locate |
| Simplified Cellular Localization | Only differentiates between nucleus, cytoplasm and shuttles between these two compartiments. | 'nucleus' (all nuclear organelles); 'cytoplasm' (all cytoplasmatic organelles) and 'shuttle' between cytoplasm and nucleus. |
| Function | For this attribute we used the UniProt ontology as a simplified version of the GO terms to provide a comprehensible overview. To annotate the network with the complete GO annotations we refer to Cytoscape plugins such as BINGO | UniProt Ontologies > Panther database |
| Connection with disease | This field is filled in when mutations, knockout or other modifications of the protein resulting in disease. If a MIM number was available it is mentioned, otherwise there is reference to specific publications. This attribute is additional information and does not mean that the PML-NBs are explicitly involved in the disease process. | UniProt (General Annotation) and literature |
| Induction | Information from UniProt and literature about regulation by several (bio)chemical stimuli. | UniProt (General Annotation) and literature |
| SUMO Consensus | We manually searched if any PML-NB components contained a predicted negatively charged amino acid-dependent sumoylation motif (NDSM) | Literature |
| SUMO Isoform | Here we provide an overview of the conjugated isoform described in literature. Proteins marked in this attribute with 'pathway' are enzymes or actors of the SUMO conjugation machinery. | Literature |
| Remarks | In the 'Remarks' attribute we provide potentially important details about the protein | Literature and/or UniProt |
| Author(s) | Reference to the first author, year of publication and PubMedID. | PubMed |
| Source | Indication of source where a certain interaction was found. | Literature and/or database (IntAct, HPRD, BIOGRID, MINT and NPD) search |
| Methods | Gives an overview of the methods used to detect the interaction. As a designation for these methods we used the same evidence code as used on BIOGRID. | Literature and/or database (IntAct, HPRD, BIOGRID, MINT and NPD) search |
| Fluorescence Microscopy | Gives details about the conditions for co-localization studies e.g. endogenous levels, overexpression data and or partial overlap (if mentioned in the publication) | Literature |
| Cell type | Cell type used for PML interaction studies. | Literature |
| PML isoform | For PML interactions it is important to make reference of the PML isoform used if this data is available. | Literature |
| Remarks | In the 'Remarks' attribute we provide potentially important details interaction | Literature |
Figure 3Functional distribution of the PML-NB components. For each functional category the number of nuclear, cytoplasmatic and shuttle proteins are plotted. The categories were based on the keywords in UniProt Ontologies. Several related categories were merged to facilitate interpretation, such as 'intracellular signaling' (merge of Notch signaling, Wnt signaling, signal transduction and intracellular signaling ontologies), 'differentation and growth' (merge of growth, differentiation, muscle development, spermatogenesis and neurogenesis), 'PTM (chemical)' (acetylaction and phosphorylation), 'RNA processes' (RNA splicing, catabolism and processing), nuclear structure (chromatin and centrosome) and miscellaneous (lipid metabolism, oncogene and phagocytosis).
Figure 4Representation of the SUMOylation pathway in relation to the PML-NB. Indicated are the proteins which have been linked to PML (blue, linked with PML). SUMO is synthesized as an immature protein which needs processing by SENPs. SENP1, SENP2 and SENP5 exert processing activity and have been linked to the PML-NBs implying that maturation may take place at the NBs. After maturation, the SUMO protein is activated by two E2 enzymes of which UBA2 was co-localized with the PML-NBs. Also the only conjugating UBC9 can be found in the PML-NBs and molecules which influence UBC9 such as p14ARF and MEL-18 have been targeted to the PML-NBs. For final conjugation of SUMO to a target protein, an E3 ligase is needed and apart from PML which potentially contains E3 activity itself, four other ligases (TOPORS, RNF4, RANBP2, PIASy) have been targeted to the NBs. We propose that the target protein, the E3 ligase and UBC9-SUMO meet at the nuclear bodies for the completion of the SUMO pathway. Finally, SUMOylation can be reversed by SENPs. Only de-conjugation SENP3 and SENP7 have not been linked to the PML-NBs thus far.
Figure 5A. Receiver Operator Curve (ROC) of our in-house prediction algorithm with Area Under the Curve (AUC) value of 0,91. B. Overlap between literature, our predictions and the predictions performed by Yang et al.. Due to the different approach there are some unique prediction data for both our prediction method and the predictions performed by Yang et al.. C. Predicted percentages by our in-house algorithm (FPR =1%). Genome-wide we predict about one fourth of the proteins to be SUMOylated. Membrane and extracellular proteins are less likely to be SUMOylation targets then cytoplasmatic or nuclear proteins. Within the PML-NBs we see a clear enrichment of SUMOylatable proteins.
Effect of SUMOylation on transcription factors present in the PML-NBs. Several transcription factors have a predicted PDSM motif but have not been shown to be SUMOylated (ARI3A, Ataxin7, FLASH, HDAC2, HHEX, HIRA, LBP1, mTOR, MZF, NCOR1, NR4A1, PAR4, PAX5, SIRT1, SKI, SP140, THAP1 and ZNF24). About the remainder of the transcription factors associated with PML-NBs there is no available data regarding SUMOylation.
| UniProtID | Name | Motif | Residue | Effect of SUMOylation | Positieve/negative Effect (+/-) |
|---|---|---|---|---|---|
| P27540 | ARNT | NDSM | K245 | SUMOylation affects the ability of ARNT to interact with cooperative molecules such as PML | - |
| Q9BYV9 | BACH2 | NDSM | SUMOylation is an important regulatory system for the mobility of the nuclear domains formed by Bach2 | + | |
| Q92793 | CBP | NDSM | SUMO modification negatively modulates the transcriptional activity of CREB-binding protein | - | |
| P01100 | C-FOS | NDSM | K299, K257 | SUMOylation down-regulates c-Fos/c-Jun AP-1 dimer activity | - |
| P05412 | C-JUN | NDSM | K257, K 229 | SUMOylation down-regulates c-Fos/c-Jun AP-1 dimer activity | - |
| P10242 | C-MYB | N/PDSM | K499, K523 | SUMO1-ylation regulates the transactivation function of c-Myb | - |
| Q9UER7 | Daxx | K630, K631 | Role of Daxx SUMOylation unknown | ||
| Q15910 | EZH2 | NDSM | Modulation of polycomb repressive complex 2 | ||
| P23769 | GATA2 | NDSM | Negative regulation of transcriptional activity | - | |
| Q13547 | HDAC1 | NDSM | K444, K476 | SUMOylation reduces HDAC1-mediated transcriptional repression | - |
| Q86Z02 | HIPK1 | NDSM | SUMOylation induces a cytoplasmic translocation leading to ASK1-JNK activation | + | |
| Q9H2X6 | HIPK2 | NDSM | K25 | SUMOylation inhibits HIPK2-induced JNK activation and p53-independent antiproliferative function | - |
| Q03933 | HSF2 | NDSM | K82 | SUMOylation of HSF2 results in conversion to the active DNA binding form | + |
| Q9UJU2 | LEF1 | SUMOylation induces potent repression of LEF1 activity | - | ||
| Q99607 | MEF/ELF4 | K657 | SUMOylation down-regulates ELF4 activity | - | |
| Q15596 | NCOA2 (human, GRIP1 mouse | NDSM | K239, K731, K788 | SUMOylation of GRIP1 (mouse equivalent of NCOA2) enhances binding to the androgen receptor | + |
| Q9Y618 | NCOR2 | N/PDSM | unknown | ||
| O95644 | NFAT | NDSM | K684, K897 | SUMOylation of K684 is required for NFAT1 transcriptional activity, SUMOylation of K897 is only required for nuclear anchorage | + |
| O00482 | NR5A2 | NDSM | K173,K289 | SUMOylation is associated with transcription repression | - |
| Q8N726 | p14ARF | N/A | Not SUMOylated. Promotes SUMOylation by enhancing UBC9 | + | |
| P04637 | p53 | K386 | SUMOylation induces premature senescence and stress response | + | |
| Q9H3D4 | p63 | K637 | SUMOylation has a negative effect on p63 driven transcription | - | |
| O15350 | p73 | K627 | SUMO1-ylation of p73 is involved its proteasome-dependent degradation, subnuclear localization and modulation of interactions with other SUMO1 substrates | - | |
| Q8N2W9 | PIASy | NDSM | K35 | SUMO1-ylation of PIASy is necessary for PIASy-dependent activation of Tcf-4 | + |
| Q05516 | PLZF | NDSM | K242, K387, K396 | SUMOylation enhances the transcriptional repression activity, correlating with a loss of PLZF-mediated growth suppression | + |
| P29590 | PML | NDSM | K65, K160, K490 | SUMOylation is important for nuclear localization of PML and nuclear body formation | + |
| P06400 | pRB | NDSM | SUMOylation induces premature senescence and stress response | + | |
| P14373 | RFP/TRIM27 | SUMOylation strengthens the transcriptional repressive activity of RFP | + | ||
| P78317 | RNF4 | N/A | SUMOylation of RNF4 not shown, RNF4 is a SUMO-dependent Ubiquitin ligase for poly-SUMOylated proteins | ||
| Q01826 | SATB1 | NDSM | K744 | SUMOylation enhances caspase cleavage of SATB1 | - |
| Q96ST3 | SIN3A | NDSM | SUMOylation regulates tumorsupression of SIN3a | ||
| Q6PEW1 | SIZN | SUMOylation mediates localization in PML-NBs | |||
| P84022 | SMAD3 | SUMOylation affects the DNA-binding activity of Smad3 and induces nuclear export | - | ||
| P08047 | SP1 | NDSM | K16 | SUMOylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription | - |
| P11831 | SRF | NDSM | K147 | Activated SRF is suppressed by its SUMOylation | - |
| Q15022 | SUZ12 | NDSM | K72, K73, K75 | SUMOylation modulates PRC2 repressive activity | +/- |
| Q9NQB0 | TCF4 | NDSM | K297 | SUMOylation is involved in beta-catenin-dependent and Tcf-4-mediated gene expression in the Wnt signaling pathway | + |
| O15164 | TIF1/TRIM24 | NDSM | K690, K708 | unknown | |
| Q92993 | TIP60 | NDSM | K430, K451 | SUMOylation of TIP60 augments its acetyltransferase activity in vitro and in vivo | + |
| P13056 | TR2 | NDSM | SUMOylated TR2 recruits corepressor RIP140 to act as a repressor for its target Oct4 | - | |
| O95551 | TTRAP | Unknown | |||
| Q9UBW7 | ZNF198 | K963 | SUMOylation of ZNF198 is important for PML body formation | + | |
| Q9Y4E5 | ZNF451 | NDSM | ZNF451 exerts its effects via SUMOylation and trafficking of transcription regulators between promyelocytic leukemia bodies and nucleoplasm |